ARTICLE | Translation in Brief
Pfizer ASPIREs to more PCSK9
Pfizer to fund studies that look more deeply at PCSK9
April 30, 2015 7:00 AM UTC
Despite the fact that two PCSK9 inhibitors are under FDA review, and a slew of others are in late stage clinical development, Pfizer Inc. wants to understand more about the target's biology.
On April 9, the company announced a new grant program for cardiovascular disease focused on PCSK9 (proprotein convertase subtilisin/kexin type 9) that aims to advance understanding of the target and foster promising scientists in the area. The program is part of the company's Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) initiative...